Table 3.

BMI in relation to endometrial cancer risk according to menopausal hormone therapy in the baseline population, and in the baseline population with detailed information on menopausal hormone therapy

BMI category (kg/m2)
Ptrend
<2525.0-29.9≥30
Baseline population
Stratification by menopausal hormone therapy status
    Never use
        Cases/person-years59/112,98898/89,459231/70,228
        Multivariate RR*1.01.98 (1.43-2.74)5.41 (4.01-7.29)<0.0001
    Former use
        Cases/person-years14/17,50319/12,42919/7,350
        Multivariate RR*1.01.81 (0.90-3.63)2.53(1.21-5.30)0.009
    Current use
        Cases/person-years127/81,04764/42,77746/21,524
        Multivariate RR*1.00.96 (0.71-1.31)1.44 (1.00-2.05)0.023
Joint effect of BMI and menopausal hormone therapy status
    Never use
        Multivariate RR*1.02.02 (1.46-2.80)5.74 (4.28-7.70)
    Former use
        Multivariate RR*1.63 (0.91-2.92)3.07 (1.83-5.16)4.82 (2.86-8.12)
    Current use
        Multivariate RR*3.40 (2.49-4.65)3.14 (2.20-4.50)4.26 (2.88-6.31)
Baseline population with detailed information on menopausal hormone therapy
    Never use
        Cases/person-years35/56,78459/43,628111/33,203
        Multivariate RR*1.02.14 (1.41-3.26)5.07 (3.42-7.52)<0.001
    Unopposed estrogen exclusively
        Cases/person-years14/8,66910/6,18710/3,969
        Multivariate RR*1.01.01 (0.44-2.28)1.63 (0.69-3.83)0.563
    Estrogen plus progestin exclusively
        Cases/person-years52/45,35629/14,73424/12,528
        Multivariate RR*1.01.00 (0.63-1.59)1.52 (0.91-2.53)0.116
  • * Adjusted for age, physical activity, personal history of diabetes, age at menarche, parity, age at menopause, oral contraceptive use, smoking, and race.

  • Women who reported mixed use of exclusive unopposed estrogen and exclusive estrogen plus progestin or unknown use are not included.